AQR Capital Management
OVID icon

AQR Capital Management’s Ovid Therapeutics OVID Stock Holding History

AQR Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,705
Closed -$5.18K – 3551
2025
Q2 		$5.18K Buy
15,705
+255
+2% +$77 ﹤0.01% 3290
2025
Q1 		$4.82K Buy
15,450
+4,811
+45% +$2.96K ﹤0.01% 3149
2024
Q4 		$9.93K Buy
+10,639
New +$11.9K ﹤0.01% 2855
2021
Q3 		– Sell
-301,767
Closed -$1.18M – 2304
2021
Q2 		$1.18M Buy
301,767
+179,708
+147% +$709K ﹤0.01% 1512
2021
Q1 		$491K Buy
122,059
+91,672
+302% +$304K ﹤0.01% 1848
2020
Q4 		$70K Sell
30,387
-20,247
-40% -$94.4K ﹤0.01% 2166
2020
Q3 		$291K Buy
+50,634
New +$339K ﹤0.01% 1924

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AQR Capital Management's OVID Position: Q3 2025 in Review

AQR Capital Management sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 15,705 shares — an estimated $5.18K sold.

AQR Capital Management first reported a position in OVID in Q3 2020 and held it in 7 quarters. The position peaked at $1.18M in Q2 2021. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • AQR Capital Management reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 15,705 Ovid Therapeutics shares in Q3 2025, an estimated $5.18K.
  • AQR Capital Management first reported a position in Ovid Therapeutics in Q3 2020 and held it in 7 quarters.
  • AQR Capital Management's Ovid Therapeutics position peaked at $1.18M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.